“We are confident that Blackstone’s global network and expertise in the sector can accelerate TCHC’s growth,” said Sakamoto.
On the other hand, Takeda President and CEO Christopher Weber commented, “Today’s transaction will provide TCHC with the ownership, resources and strategic focus to continue to thrive and meet the needs of customers, while further sharpening Takeda’s strategic focus and commitment to financial discipline and transforming science into life-changing medicines.”
Weber explained that Takeda is divesting TCHC because its growth strategy is now focused on Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies, Oncology, and Neuroscience.
“We are confident that under Blackstone, TCHC will be well-positioned to continue growing and developing its product offerings in the years to come to address the evolving needs of consumers,” said Weber.
Meanwhile, TCHC Chairman Miano Furuta said, “We believe the active and strategic investment by Blackstone will enable TCHC to maximize its potential. Blackstone is one of the world’s leading investment firms and has rich experience in the healthcare sector.”
